US05454B2043 - AXLA (XNAS)

Axcella Health Inc. Share

Overview Financial Figures

No Price

Performance

Day	Week	Month	3 Months	6 Months	1 Year	5 Years
-	-	-	-	0,00 %	705,77 %	-94,63 %

Company Profile for Axcella Health Inc. Share

Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Company Data for Axcella Health Inc. Share

Name Axcella Health Inc.

Company Axcella Health Inc.

Symbol AXLA

Website https://www.axcellahealth.com

Primary Exchange

NASDAQ

ISIN US05454B2043

Asset Class Share

Sector Healthcare

Industry Biotechnology

CEO Mr. Craig R. Jalbert CIRA

Country United States of America

Currency USD

Employees 0,0 T

Address 840 Memorial Drive, 02139 Cambridge

IPO Date 2019-05-09

Ticker Symbols

Name	Symbol
NASDAQ	AXLA

More Shares

Investors who Axcella Health Inc. hold also have the following shares in their portfolio:

FIRST TRUST NASDAQ ARTIFICIAL INTELLIGENCE AND ROBOTICS ETF ETF

I.EB.R.G.G.1.5-2.5Y U.ETF ETF

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Jobs Community Feedback Changelog

Im App Store herunterladen

Bei Google Play herunterladen

All rights reserved © LCP GmbH 2024